JPWO2020252478A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020252478A5
JPWO2020252478A5 JP2021573799A JP2021573799A JPWO2020252478A5 JP WO2020252478 A5 JPWO2020252478 A5 JP WO2020252478A5 JP 2021573799 A JP2021573799 A JP 2021573799A JP 2021573799 A JP2021573799 A JP 2021573799A JP WO2020252478 A5 JPWO2020252478 A5 JP WO2020252478A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536913A (ja
JP2022536913A5 (https=
JP7680968B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037791 external-priority patent/WO2020252478A2/en
Publication of JP2022536913A publication Critical patent/JP2022536913A/ja
Publication of JP2022536913A5 publication Critical patent/JP2022536913A5/ja
Publication of JPWO2020252478A5 publication Critical patent/JPWO2020252478A5/ja
Priority to JP2025078387A priority Critical patent/JP2025121997A/ja
Application granted granted Critical
Publication of JP7680968B2 publication Critical patent/JP7680968B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2021573799A 2019-06-14 2020-06-15 Ｐｄ－１に対する抗体およびその使用方法 Active JP7680968B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025078387A JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861638P 2019-06-14 2019-06-14
US62/861,638 2019-06-14
US201962884473P 2019-08-08 2019-08-08
US62/884,473 2019-08-08
PCT/US2020/037791 WO2020252478A2 (en) 2019-06-14 2020-06-15 Antibodies against pd-1 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025078387A Division JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Publications (4)

Publication Number Publication Date
JP2022536913A JP2022536913A (ja) 2022-08-22
JP2022536913A5 JP2022536913A5 (https=) 2023-06-20
JPWO2020252478A5 true JPWO2020252478A5 (https=) 2023-06-20
JP7680968B2 JP7680968B2 (ja) 2025-05-21

Family

ID=73782142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573799A Active JP7680968B2 (ja) 2019-06-14 2020-06-15 Ｐｄ－１に対する抗体およびその使用方法
JP2025078387A Pending JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025078387A Pending JP2025121997A (ja) 2019-06-14 2025-05-09 Ｐｄ－１に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US20220249640A1 (https=)
EP (1) EP3983444A4 (https=)
JP (2) JP7680968B2 (https=)
AU (1) AU2020291946A1 (https=)
CA (1) CA3141927A1 (https=)
WO (1) WO2020252478A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7769007B2 (ja) * 2020-12-23 2025-11-12 イミュノウェイク インコーポレイテッド イムノサイトカイン及びその使用
IL305758A (en) * 2021-03-10 2023-11-01 Immunowake Inc Immunomodulatory compounds and their uses
WO2023076177A2 (en) * 2021-10-25 2023-05-04 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US20100233154A1 (en) * 2008-10-08 2010-09-16 Medimmune Limited Targeted binding agents directed to heparanase and uses thereof 463
CA3101783C (en) * 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
CN108250303B (zh) 2016-12-19 2023-01-03 南京金斯瑞生物科技有限公司 单域抗体融合蛋白及其应用
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
US20230192839A1 (en) * 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
CN109422815A (zh) * 2017-08-28 2019-03-05 复旦大学 双特异性嵌合抗原受体c-Met/PD-1 scFv-CAR-T及其构建方法和应用
WO2020113224A2 (en) * 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof

Similar Documents

Publication Publication Date Title
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
AU2020276242B2 (en) Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
CN110511278B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
JP2020501531A5 (https=)
US11787863B2 (en) Multi-specific antibodies and methods of making and using thereof
JP2020516240A5 (https=)
JPWO2020135201A5 (https=)
JP2018532766A5 (https=)
JP2019521645A5 (https=)
JP2018502050A5 (https=)
JP2021512151A5 (https=)
JPWO2019147831A5 (https=)
CN113543809A (zh) 用于治疗癌症的免疫疗法
JP2023520587A (ja) 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
JPWO2021138474A5 (https=)
CA3202374A1 (en) Combination therapy for the treatment of cancer
JPWO2020252478A5 (https=)
JPWO2019147670A5 (https=)
WO2024173376A2 (en) Combination therapy comprising multispecific gamma delta tcr antibodies
KR20250012612A (ko) 고형 종양을 치료하는 방법
US20240101701A1 (en) Antibody-derived t cell activating technologies
US20240279333A1 (en) Multi-specific antibodies and methods of making and using thereof
JPWO2020252471A5 (https=)
EA049485B1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
JPWO2021113307A5 (https=)